Table 1.
FDA-approved seasonal influenza vaccines.
| Vaccine Type | Adjuvant | Production Platform | Dose | Age Indication |
Tradename (Manufacturer), Route |
|---|---|---|---|---|---|
| Split | None | Embryonated egg | 45 µg (15 µg HA/strain) | ≥6 mo | Afluria Quadrivalent (Seqirus), i.m./i.n. a |
| None | Embryonated egg | 45 µg (15 µg HA/strain) | ≥6 mo | Afluria Southern Hemisphere (Seqirus), i.m./i.n. a | |
| None | Embryonated egg | 45 µg (15 µg HA/strain) | ≥3 yrs | Fluarix (Glaxosmithkline), i.m. | |
| None | Embryonated egg | 45 µg (15 µg HA/strain) | ≥6 mo | FluLaval (GlaxoSmithKline), i.m. | |
| None | Embryonated egg | 60 µg (15 µg HA/strain) | ≥6 mo | FluLaval Quadrivalent (GlaxoSmithKline), i.m. | |
| None | Embryonated egg | 60 µg (15 µg HA/strain) | ≥6 mo | Fluzone Quadrivalent (Sanofi Pasteur), i.m. | |
| None | Embryonated egg | 180 µg (60 µg HA/strain) | ≥65 yrs | Fluzone High Dose Quadrivalent (Sanofi Pasteur), i.m. | |
| None | Embryonated egg | 36 µg (9 µg HA/strain) | 18–64 yrs | Fluzone-Intradermal (Sanofi Pasteur), i.d. | |
| Subunit | MF59 | Embryonated egg | 45 µg (15 µg HA/strain) | ≥65 yrs | FLUAD (Seqirus), i.m. |
| MF59 | Embryonated egg | 60 µg (15 µg HA/strain) | ≥65 yrs | FLUAD Quadrivalent (Seqirus), i.m. | |
| None | Embryonated egg | 45 µg (15 µg HA/strain) | ≥4 yrs | Fluvirin (Seqirus), i.m. | |
| None | Embryonated egg | 45 µg (15 µg HA/strain) | ≥18 yrs | Agriflu (Seqirus), i.m. | |
| None | Madin-Darby canine kidney (MDCK) cell | 60 µg (15 µg HA/strain) | ≥6 mo | Flucelvax Quadrivalent (Seqirus), i.m. | |
| Live Attenuated |
None | Embryonated egg | 106.5–7.5 FFU b virus/strain | 2–49 yrs | FluMist (AstraZeneca), i.n. |
| Recombinant | None | Baculovirus/Insect cell | 135 µg (45 µg HA/strain) | ≥18 yrs | FluBlok (Sanofi Pasteur), i.m. |
| 180 µg (45 µg HA/strain) | ≥18 yrs | FluBlok Quadrivalent (Sanofi Pasteur), i.m. |
a PharmaJet Stratis jet injector can be used for persons aged 18 through 64 years only. b FFU, fluorescent focus units.